This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
HeartRhythm
MARCH 14, 2024
Artificial intelligence (AI)-enabled sinus rhythm (SR) electrocardiogram (ECG) interpretation can aid in identifying undiagnosed paroxysmal atrial fibrillation (AF) in patients with embolic stroke of undetermined source (ESUS).
The New England Journal of Medicine
JANUARY 1, 2025
A randomized trial of the factor XIa inhibitor asundexian was stopped early owing to a higher incidence of stroke or systemic embolism than with apixaban therapy among patients with atrial fibrillation.
Frontiers in Cardiovascular Medicine
FEBRUARY 4, 2024
Anticoagulation is the mainstay of stroke prevention in appropriate patients with atrial fibrillation. An investigational class of agents which inhibit Factor XI have shown promise in pre-clinical and early clinical trials to significantly minimize bleeding while maintaining efficacy against stroke and systemic embolism.
Frontiers in Cardiovascular Medicine
MARCH 3, 2024
Background Covert atrial fibrillation (AF) is a predominant aetiology of embolic stroke of undetermined source (ESUS). Evidence suggested that AF is more frequently detected by implantable loop recorder (ILR) than by conventional monitoring.
ECG Cases
SEPTEMBER 12, 2023
The post ECG Cases 45 ECG in Weakness and Neurological Symptoms appeared first on Emergency Medicine Cases.
128 
Frontiers in Cardiovascular Medicine
DECEMBER 13, 2023
Cancer, atrial fibrillation (AF) and coronary artery disease share some common factors and interact with each other, such as obesity, aging, diabetes, and inflammation, but the potential specific mechanism is still unclear. A growing number of studies have elucidated the association between cancer and CVD.
American College of Cardiology
JANUARY 11, 2024
The goal of the ARTESIA trial was to evaluate apixaban compared with aspirin among patients with subclinical atrial fibrillation (AF).
Dr. Smith's ECG Blog
MARCH 28, 2024
male with pertinent past medical history including Atrial fibrillation, atrial flutter, cardiomyopathy, Pulmonary Embolism, and hypertension presented to the Emergency Department via ambulance for respiratory distress and tachycardia. Of course, this is NOT atrial fib, but rather PSVT, and so adenosine should work.
129 
DAIC
MARCH 31, 2025
Patients with atrial fibrillation, particularly older patients, are frequently at a high risk of bleeding. In patients with atrial fibrillation, abelacimab reduced rates of bleeding relative to rivaroxaban regardless of bleeding risk, with greater absolute safety benefit in those at higher bleeding risk.
Frontiers in Cardiovascular Medicine
JANUARY 23, 2024
A magnetic resonance imaging (MRI) pattern suggestive of an embolic etiology has been described but, to date, there are no uniformly accepted criteria. Aim The purpose of the study is to describe MRI features of ischemic cerebral lesions occurring after transcatheter ablation of atrial fibrillation (AF).
Journal of the American Heart Association
FEBRUARY 3, 2025
BackgroundLeft atrial appendage occlusion (LAAO) was associated with a high incidence of procedurerelated silent cerebral embolism (SCE). There are limited data regarding the longterm cognitive trajectory of patients undergoing LAAO.
74 
HeartRhythm
APRIL 30, 2024
Atrial fibrillation (AF) has been known as a main cause of embolic stroke. Well-chosen candidate to be anticoagulated should be critical for secondary prevention in patients with embolic stroke with undetermined source (ESUS).
HeartRhythm
APRIL 30, 2024
Cancer patients have a higher risk of atrial fibrillation (AF) than general population, however, the link between cancer and AF is not fully understood. The association between AF detected by implanted cardiac implantable electronic devices (CIEDs) and the incidence of embolic stroke has been reported.
HeartRhythm
MARCH 24, 2025
Atrial fibrillation (AF) confers significant morbidity and mortality in the form of embolic stroke, heart failure, cognitive decline, and recurrent hospitalizations as well as health care costs.1
Circulation
JANUARY 24, 2024
The primary efficacy and safety outcomes were stroke or systemic embolic events (stroke/SEE) and major bleeding, respectively; secondary outcomes were ischemic stroke/SEE, intracranial hemorrhage, death, and the net clinical outcome (stroke/SEE, major bleeding, or death).
Journal of the American Heart Association
FEBRUARY 14, 2025
BackgroundDespite proven efficacy and safety of direct oral anticoagulants (DOACs) over warfarin in patients with atrial fibrillation (AF), data on patients with AF and valvular heart disease remain scarce. The primary effectiveness outcomes were ischemic stroke or systemic embolism, and bleeding for safety.
HeartRhythm
APRIL 30, 2024
Polygenic risk score (PRS) might be useful in predicting atrial fibrillation (AF)-related stroke/systemic embolsim (SSE) before diagnosis of clinical AF.
Stroke Journal
FEBRUARY 1, 2024
Background:A considerable portion of patients with embolic stroke of unknown source(ESUS)are later found to have occult atrial fibrillation (AF). Stroke, Volume 55, Issue Suppl_1 , Page ATP223-ATP223, February 1, 2024.
Open Heart
SEPTEMBER 18, 2024
Methods We retrospectively assessed whether compliance to the ‘1–3–6–12 days rule’ was associated with the composite endpoint (recurrent stroke, systemic embolism, myocardial infarction, major bleeding or all-cause death).
Frontiers in Cardiovascular Medicine
DECEMBER 3, 2024
BackgroundThrombocytopenia is often associated with adverse outcomes in patients with atrial fibrillation. ResultsA total of 12 studies included 73,824 patients with atrial fibrillation (average age: 72.67, males: 42,275, 57.3%), among them, there were 7,673 patients combined with thrombocytopenia.
HeartRhythm
APRIL 24, 2024
Abnormal conduction, structure and function of the atrial myocardium predispose to atrial fibrillation (AF) and stroke. Usefulness of electrocardiographic (ECG) indices in predicting stroke or systemic embolism (SSE) in patients undergoing cardioversion for AF remains unknown, especially in those at low estimated risk.
HeartRhythm
APRIL 30, 2024
Atrial fibrillation(AF) is associated with increased risk of embolic stroke and heart failure hospitalizations in patients with hypertrophic cardiomyopathy(HCM).
The New England Journal of Medicine
NOVEMBER 11, 2023
In a randomized trial involving patients with subclinical (typically asymptomatic) atrial fibrillation, apixaban led to a lower risk of stroke or systemic embolism than aspirin but a higher risk of major bleeding.
HeartRhythm
APRIL 30, 2024
Clinical, imaging, and genetic markers in combinations might be useful for risk assessment of atrial fibrillation (AF) and related stroke/systemic embolsim (SSE).
Medical Xpress - Cardiology
SEPTEMBER 3, 2024
Mass screening for atrial fibrillation using ECG together with heart failure biomarker does not prevent ischemic stroke or systemic embolism (blood clot) in older adults aged 75–76 years over 5 years follow-up, according to late breaking research presented in a Hot Line Session at this year's ESC Congress 2024 in London, UK (30 Aug–2 Sept).
Journal of the American Heart Association
MARCH 21, 2025
BackgroundThe clinical utility of the polygenic risk score in predicting cardiovascular events in patients with atrial fibrillation (AF) has not yet been established. years), the incidence rates of ischemic stroke or systemic embolism, myocardial infarction, and heart failure hospitalization were 0.83, 0.42, and 0.61
HeartRhythm
APRIL 30, 2024
Embolic stroke of undetermined source (ESUS), a subset of cryptogenic stroke, which excludes small-vessel disease cause, has a high recurrence rate and is a subgroup in need of further characterisation and treatment optimisation. AF detection rates with implantable cardiac monitoring (ICM) following cryptogenic stroke are >12% at 12 months.
40 
DAIC
FEBRUARY 27, 2024
Bernard's Heart & Vascular Center , Jonesboro, Arkansas) mark a significant milestone in the pursuit of innovative solutions for non-valvular atrial fibrillation (NVAF) treatment. Patients with NVAF deemed appropriate for LAAX to reduce the risk of stroke and systemic embolism, will participate in this research effort.
Stroke Journal
DECEMBER 21, 2023
Nonvalvular atrial fibrillation is a common rhythm disorder of middle-aged to older adults that can cause ischemic strokes and systemic embolism. Stroke, Volume 55, Issue 1 , Page 214-225, January 1, 2024.
Journal of the American Heart Association
JANUARY 31, 2024
BackgroundThere are limited data on the efficacy and safety of direct oral anticoagulants (DOACs) in patients with atrial fibrillation with significant tricuspid regurgitation (TR), which can lead to hepatic dysfunction and intestinal malabsorption. The median follow‐up duration was 2.4 1.06];P=0.11).
HeartRhythm
APRIL 30, 2024
Cryoablation for atrial fibrillation is a widely used technique for pulmonary vein isolation. Known complications associated with cryoablation include tamponade, phrenic nerve injury, stroke, pulmonary embolism, pulmonary vein stenosis, and atrioesophageal fistulas.
Open Heart
MARCH 1, 2024
Background Amiodarone is an established treatment for atrial fibrillation (AF) but might interfere with the metabolism of apixaban or warfarin. Exploratory outcomes included ischaemic stroke/systemic embolism and all-cause/cardiovascular (CV) mortality. Methods Retrospective observational study using Swedish health registers.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4141940-A4141940, November 12, 2024.
Stroke Journal
JANUARY 30, 2025
Background:Stroke is the second leading cause of death worldwide, with atrial fibrillation being a significant risk factor that substantially increases the likelihood of stroke. The primary efficacy outcome of the study was the composite endpoint of either stroke or systemic embolism. to 0.87, p = 0.005). to 1.38, p = 0.72).
Open Heart
JANUARY 29, 2024
Aim To assess outcomes after cardiac surgery with biological valve replacement, valve repair or transcatheter aortic valve implantation (TAVI) in patients with atrial fibrillation (AF) in accordance with oral anticoagulant (OAC) treatment. Methods All patients in Sweden undergoing valvular intervention with AF were included.
DAIC
JANUARY 24, 2025
Affecting 60 million people worldwide 1 , the prevalence of atrial fibrillation (AFib) is expected to increase by 60% by 2050 due to an aging population and rising cardiometabolic risk factors 2. In addition, the Centers for Disease Control and Prevention (CDC) estimates that more than 12 million Americans will have AFib by 2030 3.
52 
ECG Cases
AUGUST 13, 2019
Ian Stiell on atrial fibrillation rate vs rhythm control controversy, Justin Morgenstern on peripheral vasopressors: safe or unsafe? Michelle Klaiman, Taryn Lloyd on motivational interviewing that makes a difference to patient's lives.
Stroke Journal
FEBRUARY 1, 2024
We isolated a cohort of patients with likely embolic PCA occlusions (those with atrial fibrillation) and compared outcomes associated with IVT and EVT versus medical management (MM).Methods:The to 2.87) with no difference in length of hospital stay (adjusted β 0.26, 95% -0.71 to 2.47) as compared to patients treated with MM.
Journal of the American Heart Association
NOVEMBER 28, 2023
BackgroundAlthough older patients with atrial fibrillation are at heightened risk of thromboembolic and bleeding events, their optimal treatment choice remains uncertain.Methods and ResultsThis meta‐analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines. prospero/.
Journal of Cardiovascular Electrophysiology
DECEMBER 23, 2024
ABSTRACT Background Anemia is frequently observed as a comorbidity in atrial fibrillation (AF), especially in elderly patients and in those on anticoagulation. However, the impact of anemia did not significantly affect the risk of stroke, transient ischemic stroke (TIA), or systemic embolism (HR: 1.07
Stroke Journal
JANUARY 30, 2025
Renal dysfunction increases risk of atrial fibrillation, ischemic stroke and systemic bleeding. Subjects with other indication for anticoagulation such as venous thromboembolism, pulmonary embolism, and prosthetic valve were excluded. Stroke, Volume 56, Issue Suppl_1 , Page AWP171-AWP171, February 1, 2025.
Journal of the American Heart Association
JANUARY 19, 2024
The primary efficacy and safety end points were stroke or systemic embolism and major bleeding (International Society on Thrombosis and Hemostasis definition), respectively. The stroke or systemic embolism rate was lower with edoxaban than placebo in both weight groups (≤45 kg: hazard ratio [HR], 0.36 [95% CI, 0.16–0.80];
Stroke Journal
JANUARY 30, 2025
Background:Patients with atrial fibrillation (AF) and previous stroke or transient ischemic attack (TIA) are at high risk of recurrent stroke. Heterogeneity was examined using I2statistics.Results:We included 7 RCTs and 2 non-RCTs comparing NOAC to warfarin in patients with atrial fibrillation and previous stroke or TIA.
American College of Cardiology
JUNE 12, 2024
The baseline CHA2DS2-VASc score helped to identify patient with subclinical atrial fibrillation (SCAF) in whom the benefit for reducing the risk of stroke and systemic embolism (SE) with an oral anticoagulant (OAC) was greater than the risk of increased major bleeding, according to a subgroup analysis from the ARTESiA study presented at Heart Rhythm (..)
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content